Edition:
United Kingdom

People: Consun Pharmaceutical Group Ltd (1681.HK)

1681.HK on Hong Kong Stock

4.99HKD
20 Jun 2019
Change (% chg)

HK$0.04 (+0.81%)
Prev Close
HK$4.95
Open
HK$4.95
Day's High
HK$5.05
Day's Low
HK$4.92
Volume
672,000
Avg. Vol
1,311,003
52-wk High
HK$7.95
52-wk Low
HK$4.18

Li, Qian 

Ms. Li Qian is Chief Executive Officer, Executive Vice Chairlady of the Board of Consun Pharmaceutical Group Limited. Ms. LI has over 27 years of experience in the business of pharmaceutical industry, with nearly 10 years of experience in medical education. Ms. LI worked at Southern Medical University from October 1989 to April 1998. Ms. LI joined the Group in 1997 when Consun Pharmaceutical was newly set-up, as the associate director of general manager’s office, human resources manager, deputy executive general manager and deputy sales general manager of Guangzhou Consun Pharmaceutical Company Limited (“GZ Consun”), a subsidiary of the Group. Ms. LI has also served as a director and the general manager (which was redesignated as president in May 2008) of GZ Consun since November 1999. Ms. LI obtained a master’s degree in business administration at Asia International Open University (Macau) in November 2007. She has obtained 3 invention patents and published research papers on the “Chinese journal of Clinical Medicinewarded as Excellent Private Entrepreneur by Tongliao City People’s Government of the Inner Mongolia Autonomous Region in July 2008, and a Model Worker (????) by Inner Mongolia People’s Government in April 2010. In December 2010, she obtained the Third Prize for Technological Progress in the Inner Mongolia Autonomous Region In December 2011, she was recognised as Famous Entrepreneur in Pharmaceutical Industry of Guangdong Province by Guangdong Province Pharmaceutical Industry Association. In April 2014, she was elected as Chinese Pharmaceutical Brand Woman. In February 2017, she was accredited as Excellent Entrepreneur in Pharmaceutical Industry of Guangdong Province , in March 2017 obtained the First Prize for Technological Progress in Yulin City and in December 2017 was awarded the “Best Business Leader Award” by “China Finance”. Ms. LI is a member of the Standing Committee of the Encephalopathy Medicine Research Professional Committee of China Association of Traditional Chinese Medicine.

Basic Compensation

Total Annual Compensation, CNY 4,673,000
Restricted Stock Award, CNY --
Long-Term Incentive Plans, CNY --
All Other, CNY 9,667,000
Fiscal Year Total, CNY 14,340,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Yubao An

14,401,000

Qian Li

14,340,000

Ning Tang

--

Quan Zhu

3,851,000

Lanfen Fang

--

Pei Cheng Fang

--
As Of  31 Dec 2014